Arrowhead Pharmaceuticals Inc
ARWR29.075USD
+1.075+3.84%
收盘 09/05, 16:00（美东）报价延迟15分钟
4.02B总市值
亏损市盈率 TTM
关于 Arrowhead Pharmaceuticals Inc 公司
Arrowhead Pharmaceuticals, Inc. 开发通过抑制致病基因来治疗难治性疾病的药物。该公司的疗法使用广泛的核糖核酸 (RNA) 化学和递送方式，触发 RNA 干扰 (RNAi) 机制，从而快速、深度和持久地敲除目标基因。该公司的靶向 RNAi 分子 (TRiMTM) 平台利用配体介导的递送，旨在实现组织特异性靶向，同时结构简单。它专注于各种治疗领域，例如心脏代谢、肺部、肝脏、肌肉和中枢神经系统。它拥有大约 14 种临床阶段研究药物（9 种全资和 5 种合作），开发阶段从 I 期到 III 期不等。该公司的管道产品包括Plozasiran、Zodasiran、Olpasiran、ARO-RAGE、ARO-MUC5AC、ARO-MMP7、GSK-4532990、Fazirsiran、JNJ-3989、HZN-457、ARO-C3、ARO-PNPLA3、ARO-DUX4和ARO-SOD1。
公司简介
公司代码ARWR
公司名称Arrowhead Pharmaceuticals Inc
上市日期Dec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
员工数量609
证券类型Ordinary Share
年结日Dec 14
公司地址177 E Colorado Blvd
城市PASADENA
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编91105
电话16266964702
网址https://arrowheadpharma.com/
公司代码ARWR
上市日期Dec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
37.94K
+0.01%
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
35.78K
-2.60%
Mr. Daniel Apel
Mr. Daniel Apel
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
其他
60.00%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
其他
60.00%
股东类型
持股股东
占比
Investment Advisor
41.14%
Investment Advisor/Hedge Fund
23.06%
Hedge Fund
7.19%
Individual Investor
4.44%
Research Firm
2.60%
Sovereign Wealth Fund
1.39%
Bank and Trust
0.96%
Pension Fund
0.95%
Venture Capital
0.18%
其他
18.08%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
583
126.42M
91.54%
+6.47M
2025Q1
603
125.23M
90.71%
+6.54M
2024Q4
609
108.09M
85.81%
-8.58M
2024Q3
605
106.83M
85.95%
-7.44M
2024Q2
608
107.20M
86.35%
-5.57M
2024Q1
621
105.82M
85.63%
+13.72M
2023Q4
625
87.51M
81.46%
-1.31M
2023Q3
624
83.79M
78.09%
-822.40K
2023Q2
641
80.82M
75.59%
-4.71M
2023Q1
648
81.64M
75.46%
-182.63K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
18.18M
13.17%
+3.66M
+25.22%
Mar 31, 2025
The Vanguard Group, Inc.
13.18M
9.54%
+1.02M
+8.37%
Mar 31, 2025
Avoro Capital Advisors LLC
11.11M
8.05%
--
--
Mar 31, 2025
State Street Global Advisors (US)
7.00M
5.07%
+983.02K
+16.34%
Mar 31, 2025
Slate Path Capital LP
5.23M
3.79%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
3.32M
2.4%
-1.74M
-34.40%
Mar 31, 2025
Anzalone (Christopher Richard)
3.92M
2.84%
-141.12K
-3.47%
Apr 11, 2025
Geode Capital Management, L.L.C.
2.95M
2.14%
-4.63K
-0.16%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.67M
1.93%
-231.80K
-7.99%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Invesco Biotechnology & Genome ETF
2.8%
Global X Genomics & Biotechnology ETF
2.22%
ROBO Global Healthcare Technology & Innovation ETF
1.58%
Invesco S&P SmallCap Health Care ETF
1.34%
ALPS Medical Breakthroughs ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
1.15%
Tema Heart & Health ETF
1.02%
SPDR S&P Biotech ETF
0.56%
WisdomTree BioRevolution Fund
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.44%
查看更多
Invesco Biotechnology & Genome ETF
占比2.8%
Global X Genomics & Biotechnology ETF
占比2.22%
ROBO Global Healthcare Technology & Innovation ETF
占比1.58%
Invesco S&P SmallCap Health Care ETF
占比1.34%
ALPS Medical Breakthroughs ETF
占比1.31%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.15%
Tema Heart & Health ETF
占比1.02%
SPDR S&P Biotech ETF
占比0.56%
WisdomTree BioRevolution Fund
占比0.45%
Invesco NASDAQ Future Gen 200 ETF
占比0.44%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
